OGN
Organon & Co.
NYSE · Healthcare · Drug Manufacturers - General · US
$13.68
−0.07%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$13.68
From 52W high−0.73%
Volume4.94M
Market cap$3.59B
P/E (TTM)17.3x
P/S (TTM)0.6x
Div yield0.58%
Key dataSep 18, 2026
Open
$13.68
From 52W high
−0.73%
Volume
4.94M
Market cap
$3.59B
ValuationView details →
P/E (Fwd)
3.9x
EV/EBITDA
8.4x
P/E (TTM)
17.3x
RSI (14)
53.0
MomentumView details →
1D Return
−0.07%
YTD Return
+91.00%
SummaryUpdated Jun 1, 2026
Organon & Co. (NYSE:OGN) is a global healthcare company that was spun off from Merck & Co. in 2021, focusing on women's health, biosimilars, and established pharmaceutical brands. Founded as an independent entity in 2020 and incorporated in Jersey City, New Jersey, the company went public in May 2021. Organon operates as a specialty pharmaceutical company with a diverse portfolio of prescription therapies sold in the United States and internationally, serving healthcare providers, patients, and health systems worldwide.
Similar companies
Latest newsMore news →
Organon signed agreements with Population Services International India and Ipas Development Foundation as recipients of its 2026 Her Health Grants, supporting adolescent girls' health in Bihar and contraceptive access in Uttar Pradesh.2d agoAlibaba Health Pharmacy announced a three-year strategy to shift from online medicine purchasing to bringing medicines closer to users and launched the 'Drug Full-Stack' strategic partnership with Sansheng Mandi, Daan Pharmaceutical, Daiichi Sankyo (China) Investment, and Organon.4d ago